Age dependence of modern clinical risk groups for localized prostate cancer—A population-based study
Cancer Jan 12, 2020
Huynh-Le MP, Myklebust TA, Feng CH, et al. - As in optimal prostate cancer (PCa) screening strategies, men likely to have potentially lethal disease are the main focus, researchers examined if age-specific incidence rates (ASIRs) by modern clinical risk groups could aid in risk stratification efforts for screening. They performed a cross-sectional population study recognizing all men diagnosed with PCa in Norway from 2014 to 2017 (n = 20,356). Outcomes revealed a significant association of older age with a higher Gleason score and more advanced disease. Among men aged 55 to 59, 65 to 69, 75 to 79, and 85 to 89 years, 16.5%, 23.4%, 37.2%, and 59.9%, respectively, had Gleason 8 to 10 disease; in the same age groups, 29.3%, 39.1%, 60.4%, and 90.6%, respectively, had at least high-risk disease. For low-risk, favorable intermediate-risk, unfavorable intermediate-risk, high-risk, regional, and metastatic disease, they noted maximum ASIRs (per 100,000 men) of 157.1 for those aged 65 to 69 years, 183.8 for those aged 65 to 69 years, 194.8 for those aged 70 to 74 years, 408.3 for those aged 75 to 79 years, 159.7 for those aged ≥ 85 years, and 314.0 for those aged ≥ 85 years, respectively. Findings support performing screening as beneficial in healthy older men.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins